Chiugray, you’re exactly right on the immunology. NK cells are part of the innate immune system, not the adaptive arm. They can kill tumor cells rapidly and non-specifically, but they don’t create the long-lived, antigen-specific memory that’s needed for durable protection or true “immune cures.” Once NK activity fades, there’s nothing in that mechanism to ensure the cancer won’t come back unless another component of the immune system has been trained.
That’s the key distinction with DCVax. By loading dendritic cells with the entire antigen profile from a patient’s tumor, you’re directly activating the adaptive immune system, priming CD4+ helper and CD8+ killer T cells that not only attack now, but also differentiate into memory cells. Those memory cells patrol for years, ready to mount a rapid, targeted response if the same cancer antigens reappear.
It’s why NK-heavy regimens like BioStripe can sometimes produce dramatic short-term results, but DCVax is designed for both immediate tumor clearance and durable immune surveillance. In other words, NK cells can help knock the door down, but DCVax trains the guards to keep it locked for good.
Bullish
Market Data 
Markets 
